The Government plan for UK life science companies after Brexit

Lord O’Shaughnessy delivered a speech at the UK Bioindustry Association(BIA)/MHRA Conference which addressed the concerns of the industry and the commitment of the Government to “support and promote” the pharmaceutical sector through the Brexit negotiations. In line with the recent letter from Health and Business Secretaries in the Financial Times, Lord O’Shaughnessy highlighted that the expected collaboration between the UK and the EU would follow these guiding principles:

  • Patients will be considered a priority and must never be disadvantaged
  • The UK will continue to have a major role in Europe and globally with prime importance given to promoting and ensuring public health
  • Arrangements will be sought that support quick and simple entry of products in the UK market, with the UK and Europe having a significant impact on medical innovation

Steve Bates, CEO of the BIA agreed with the plan set by the Government and mentioned:

This builds on the helpful statement provided by Secretaries of State Jeremy Hunt and Greg Clark last week. The BIA will continue to share our members’ expertise with government throughout the negotiation process and continue the ‘positive level of engagement and debate’ that has occurred so far between us.

To read more about this, please click here.

Published on 14. July 2017 in News UK